Physician profile
Ge Qu
NPI 1447888722
$2,607.04
in general payments reported to CMS, 2019-2025
4 companies · $2,607 in 2025
The $2,607 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $2,607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,864 · Food and Beverage: $743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,864.06 |
| Food and Beverage | $742.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,148.61 | 2025 | Proclaim |
| Medtronic, INC. | $1,141.13 | 2025 | Intellis Adaptivestim |
| Stryker Corporation | $170.17 | 2025 | Mild Device Kit |
| Nalu Medical, INC. | $147.13 | 2025 | Nalu Neurostimulation System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ge Qu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.